GIM
CRSP icon

Granahan Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Granahan Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-52,006
Closed -$3.4M – 172
2022
Q3 		$3.4M Buy
52,006
+2,230
+4% +$162K 0.11% 144
2022
Q2 		$3.02M Sell
49,776
-42,330
-46% -$2.49M 0.1% 147
2022
Q1 		$5.78M Buy
92,106
+44,565
+94% +$2.8M 0.14% 127
2021
Q4 		$3.6M Buy
47,541
+2,211
+5% +$193K 0.07% 164
2021
Q3 		$5.07M Sell
45,330
-5,962
-12% -$749K 0.1% 149
2021
Q2 		$8.3M Buy
51,292
+3,017
+6% +$367K 0.15% 125
2021
Q1 		$5.88M Sell
48,275
-8,922
-16% -$1.35M 0.12% 132
2020
Q4 		$8.76M Buy
57,197
+17,863
+45% +$2.11M 0.2% 101
2020
Q3 		$3.29M Sell
39,334
-4,291
-10% -$381K 0.11% 129
2020
Q2 		$3.21M Buy
43,625
+9,498
+28% +$555K 0.12% 127
2020
Q1 		$1.45M Sell
34,127
-455
-1% -$23.5K 0.08% 151
2019
Q4 		$2.11M Hold
34,582
– – 0.1% 139
2019
Q3 		$1.42M Buy
34,582
+2,655
+8% +$127K 0.08% 150
2019
Q2 		$1.5M Sell
31,927
-730
-2% -$29.2K 0.07% 155
2019
Q1 		$1.17M Sell
32,657
-2,335
-7% -$80.7K 0.06% 167
2018
Q4 		$1M Sell
34,992
-12,350
-26% -$429K 0.07% 165
2018
Q3 		$2.1M Sell
47,342
-47,449
-50% -$2.48M 0.11% 153
2018
Q2 		$5.57M Buy
94,791
+8,048
+9% +$458K 0.34% 93
2018
Q1 		$3.96M Sell
86,743
-54,397
-39% -$2.25M 0.29% 104
2017
Q4 		$3.31M Sell
141,140
-122,606
-46% -$2.33M 0.26% 116
2017
Q3 		$4.71M Buy
263,746
+89,839
+52% +$1.63M 0.39% 93
2017
Q2 		$2.79M Buy
+173,907
New +$2.87M 0.26% 116

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Granahan Investment Management's CRSP Position: Q4 2022 in Review

Granahan Investment Management sold out of CRISPR Therapeutics (CRSP) in Q4 2022, closing a stake of 52,006 shares — an estimated $3.4M sold.

Granahan Investment Management first reported a position in CRSP in Q2 2017 and held it in 22 quarters. The position peaked at $8.76M in Q4 2020. 396 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

  • Granahan Investment Management reported no remaining CRISPR Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Granahan Investment Management sold 52,006 CRISPR Therapeutics shares in Q4 2022, an estimated $3.4M.
  • Granahan Investment Management first reported a position in CRISPR Therapeutics in Q2 2017 and held it in 22 quarters.
  • Granahan Investment Management's CRISPR Therapeutics position peaked at $8.76M in Q4 2020.
  • 396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on Granahan Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.